ProfoundBio Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 110

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.91B

ProfoundBio General Information

Description

Developer of novel targeted therapeutics intended to treat patients with cancer. The company develops advancing novel classes of therapeutics that are designed to leverage the immune system to eradicate cancer, enabling patients to get better treatment with curative potential.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 401 Terry Avenue North
  • Seattle, WA 98109
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 401 Terry Avenue North
  • Seattle, WA 98109
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ProfoundBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 21-May-2024 $1.91B Completed Clinical Trials - Phase 2
4. Later Stage VC (Series B) 09-Feb-2024 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A1) 14-Apr-2022 Completed Product Development
2. Early Stage VC (Series A) 16-Jun-2021 $55.5M $68M Completed Product Development
1. Early Stage VC 20-Aug-2020 $12.5M $12.5M Completed Startup
To view ProfoundBio’s complete valuation and funding history, request access »

ProfoundBio Patents

ProfoundBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025117639-A1 Antibodies and methods for ptk7 detection Inactive 27-Nov-2023
WO-2025072486-A1 Dosage of antibody drug conjugate rinatabart sesutecan Inactive 26-Sep-2023
WO-2025072406-A1 Ptk7 binding agents, conjugates thereof and methods of using the same Inactive 26-Sep-2023
WO-2025064521-A1 Ultrafiltration / diafiltration purification methods Inactive 18-Sep-2023
WO-2024149345-A1 Linkers, drug linkers and conjugates thereof and methods of using the same Inactive 11-Jan-2023 A61K47/68031
To view ProfoundBio’s complete patent history, request access »

ProfoundBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ProfoundBio Former Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ally Bridge Group Growth/Expansion Minority
B Capital China Venture Capital Minority
Chang'an Fund Management Venture Capital Minority
Dragonball Capital Corporate Venture Capital Minority
Gaorong Ventures Venture Capital Minority
You’re viewing 5 of 22 investors. Get the full list »

ProfoundBio FAQs

  • When was ProfoundBio founded?

    ProfoundBio was founded in 2018.

  • Where is ProfoundBio headquartered?

    ProfoundBio is headquartered in Seattle, WA.

  • What is the size of ProfoundBio?

    ProfoundBio has 110 total employees.

  • What industry is ProfoundBio in?

    ProfoundBio’s primary industry is Drug Discovery.

  • Is ProfoundBio a private or public company?

    ProfoundBio is a Private company.

  • What is the current valuation of ProfoundBio?

    The current valuation of ProfoundBio is .

  • What is ProfoundBio’s current revenue?

    The current revenue for ProfoundBio is .

  • How much funding has ProfoundBio raised over time?

    ProfoundBio has raised $250M.

  • Who are ProfoundBio’s investors?

    Ally Bridge Group, B Capital China, Chang'an Fund Management, Dragonball Capital, and Gaorong Ventures are 5 of 22 investors who have invested in ProfoundBio.

  • When was ProfoundBio acquired?

    ProfoundBio was acquired on 21-May-2024.

  • Who acquired ProfoundBio?

    ProfoundBio was acquired by Genmab.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process